Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

KERASTOP

Financiado

Cerrado

A big jump in preventing problems in refractive surgery for myopia

The treatment of myopia using the excimer laser technology has been standardized globally. It is the main business for ophthalmologists in private practice. Most of patients undergoing laser refractive surgery achieve a good outco... ver más

31/08/2017

CORNEA PROJECT

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

CORNEA PROJECT La investigacion, desarrollo, fabricacion, empaquetado, promocion, comercializacion, venta, distribucion, importacion y exportacion de dispo...

TRL 3-4 | 130K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-08-31

SMEInst-03-2016-2017: Dedicated support to biotechnology...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

CORNEA PROJECT

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC2019-007303-1 DIAGNÓSTICO MOLECULAR DISRUPTIVO PARA ELIMINAR EL RIESGO EN... 595K€ Cerrado

PID2020-115191RB-I00 NUEVOS PARADIGMAS DE DISEÑO, SELECCION Y EVALUACION DE LENTE... 169K€ Cerrado

MD-SD-OCT An innovative double technologies medical device for corneal... 2M€ Cerrado

SimVisSim Simultaneous Vision Simulator for optimizing selection of pr... 150K€ Cerrado

IRWAVE Imaging Refractor Wide Angle Vision Evaluation 153K€ Cerrado

OCT4IOL Optical Coherence Tomography for Intraocular Lenses 150K€ Cerrado

Duración del proyecto: 3 meses Fecha Inicio: 2017-05-08
Fecha Fin: 2017-08-31

Líder del proyecto

CORNEA PROJECT La investigacion, desarrollo, fabricacion, empaquetado, promocion, comercializacion, venta, distribucion, importacion y exportacion de dispo...

TRL 3-4 | 130K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The treatment of myopia using the excimer laser technology has been standardized globally. It is the main business for ophthalmologists in private practice. Most of patients undergoing laser refractive surgery achieve a good outcome, but there is a reduced volume of patients that develop a devastating disease, the post-LASIK ectasia. This condition is due to the performance of surgery in eyes with a pathology called keratoconus. It is not completely understood and generates a degradation of vision, with the potential of leading to extreme conditions requiring corneal transplantation. It is a very traumatic situation for both patients and doctors. Nowadays, keratoconus is only diagnosed when clinical signs are present. Ophthalmologists search for signs in the corneal surface indicating the potential presence of keratoconus and preventing the risk for the development of the disease. This leads to the avoidance of performing surgery in a great volume of patients due to a theoretical risk of ectasia development. CORNEA PROJECT has two biomarkers directly related to the presence of keratoconus. Based on the use of these biomarkers, KERASTOP will provide a fast in situ diagnostic test, with high levels of sensitivity and specificity (over 90%) that will facilitate the doctor to determine if the pathology is present, even in very initial stages not detected with the current diagnostic tests. KERASTOP will reduce the risks in refractive surgery, will increase the volume of candidates suitable for surgery and will allow the performance of more surgeries with more safety. CORNEA PROJECT is composed of two foundational partners with more than 15 years of experience in the laser refractive surgery sector worldwide. Likewise, the company has a human team composed of very relevant experts in the area of biotechnology and ophthalmology. In 5 years, the company is expected to have a positive EBITDA of more than 30 million of euros and to have generated more than 90 employments.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores